MNKD

About Mannkind Corporation (MNKD) Stock

Mannkind Corporation (MNKD) closed the 2026-09-18 session at $3.54, down 1.12% versus the previous close (-0.04). The stock opened at $3.59 and traded between $3.50 and $3.62 during that session. Session trading volume was 5.5M shares. The volume-weighted average price (VWAP) is $3.54.

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.

Mannkind Corporation has a market capitalization of $1.14 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. MNKD is listed on the XNAS exchange. The company employs approximately 592 people. Mannkind Corporation is headquartered in DANBURY, CT. The recorded listing date is 2004-07-28.

On this page you can find market MNKD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.